ReviewClinical microbiology reviews2010
The changing microbial epidemiology in cystic fibrosis.
Review in Clinical microbiology reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 423 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
423 citing papers in PubMed, 3 syntheses or guidelines pooled it, 798 citations in OpenAlex.
- Antibiotic therapy for chronic infection with <I>Burkholderia cepacia</I> complex in people with cystic fibrosis.The Cochrane database of systematic reviews · 2021Pooled it
- Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis.The Cochrane database of systematic reviews · 2019Pooled it
- Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis.The Cochrane database of systematic reviews · 2019Pooled it
- Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.Annals of the American Thoracic Society · 2024Trial
- Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Trial
- GrowingInfection and immunity · 2026Article
- Dynamic balance of the lung microbiome in health and respiratory diseases.Chinese medical journal · 2026Review
- Design of solid phase microextraction patches for the detection of volatile metabolites associated with Burkholderia cepacia.Applied microbiology and biotechnology · 2026Article
- Targeting Periodontitis with Treg-Derived Extracellular Vesicles: Modulation of Macrophages and CD8International journal of molecular sciences · 2026Article
- Article
- Strain-specific persistence ofJournal of medical microbiology · 2026Article
- Article
- Total Synthesis ofJournal of the American Chemical Society · 2026Article
- The secretome of the environmental bacteriumMicrobiology spectrum · 2026Article
- Comparative genomic analyses shed light on the introduction routes of rice-pathogenic Burkholderia gladioli strains into Bangladesh.BMC genomics · 2026Article
- Necrotizing pneumonia and septic shock caused byIDCases · 2026Article
- Microbial and host innate immune factors affecting the persistence ofFrontiers in cellular and infection microbiology · 2026Review
- Antibiotic susceptibility testing ofFrontiers in microbiology · 2026Article
- Review
- Interkingdom signaling elicited by bacterial extracellular vesicles in human cystic fibrosis airway epithelium and neutrophils.Frontiers in cellular and infection microbiology · 2026Article
363 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection of the airways remains the primary cause of morbidity and mortality in persons with cystic fibrosis (CF). This review describes salient features of the epidemiologies of microbial species that are involved in respiratory tract infection in CF. The apparently expanding spectrum of species causing infection in CF and recent changes in the incidences and prevalences of infection due to specific bacterial, fungal, and viral species are described. The challenges inherent in tracking and interpreting rates of infection in this patient population are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.